Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
The FDA approved Boehringer Ingelheim's COPD treatment Striverdi Respimat, a once-a-day inhaler the German drugmaker hopes can contend in a crowded respiratory market.
California biotech Cold Genesys has wrapped up a $13.6 million A round to support its work on cancer treatment that promises to infect tumor cells and convince the immune system to join the fight.
AstraZeneca's internal forecast for a bright future is heavily dependent on a cache of new cancer immunotherapies, and the U.K. drugmaker is planning to test its lead oncology treatment in more and more tumor types with hopes of delivering on a $6.5 billion peak sales estimate.
Menlo Park, CA's Avalanche Biotechnologies pulled off a $102 million Wall Street debut, planning to spend its new cash on a pipeline of gene therapies for ocular diseases.
Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients' bad cholesterol.
AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.
After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit its chief executive's power, according to a report, especially when it comes to meetings with the FDA over the biotech's much-scrutinized lead drug.
Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.
Months after a swift exit from Pfizer's highest ranks, Amy Schulman has made her next move, joining high-profile biotech investor Polaris as a venture partner
KaloBios was an early entrant in 2013's boom of biotech IPOs, touting its development technology as a springboard for high-quality antibodies. A year later, that promise hasn't come to fruition, and partner Sanofi is walking away from an antibacterial program for which the company had high hopes.